Kisunla (Donanemab-azbt)

Kisunla (donanemab-azbt) is an innovative amyloid beta-directed antibody used in treating early symptomatic Alzheimer’s disease (AD). It targets adults with mild cognitive impairment (MCI) and early-stage dementia caused by AD, confirmed through amyloid pathology, offering hope for improved Alzheimer’s care.

Recommended Dosage: The recommended dosage of Donanemab-azbt is 700 mg administered as an intravenous (IV) infusion over approximately 30 minutes every four weeks for the first three doses, followed by 1400 mg every four weeks.

Consider stopping dosing based on the reduction of amyloid plaques to minimal levels on amyloid PET imaging. Obtain a recent baseline brain MRI before initiating treatment.  

• Amyloid Related Imaging Abnormalities (ARIA) are serious potential risks associated with Kisunla 350 mg/20 mL (17.5 mg/mL) injections. Patients receiving Kisunla should undergo regular MRI scans to monitor for ARIA, as it may lead to brain swelling or microhemorrhages, especially in the early stages of treatment.
  
• Treatment with Kisunla 350 mg/20 mL injection may cause hypersensitivity reactions, including rash, itching, or severe allergic responses. Immediate discontinuation of the drug is advised if signs of hypersensitivity occur. Close monitoring is crucial, and medical intervention may be required for such reactions.
  
• Treatment with donanemab-azbt may trigger infusion-related reactions, such as fever, chills, or nausea. Patients should be monitored during and after administration for potential symptoms. Pre-medication and appropriate clinical management can help minimize the risk of severe infusion reactions.
  
• The safety of this therapeutic drug during pregnancy has not been established. It should be used during pregnancy only if the potential benefits justify the risks. Pregnant women are advised to consult their healthcare provider before starting treatment.
  
• There is no data on the presence of donanemab-azbt in human milk, and its effects on breastfeeding infants are unknown. Breastfeeding mothers should discuss the potential risks and benefits of treatment with their healthcare provider before use.
  

What documents are required to import KISUNLA to India?

KISUNLA (donanemab-azbt) injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable
  
• Is KISUNLA available in India?

• IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
  
• On availability of Kisunla in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of KISUNLA (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Kisunla 350 mg/20 mL price in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source the KISUNLA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Kisunla®?

Donanemab-azbt is a Generic Name for the trade name drug Kisunla®.

What is the Manufacturer’s Name of Kisunla®?

Kisunla® is manufactured by Eli Lilly and Company.

Is Kisunla® approved by the FDA?

Yes, Kisunla® is approved by the FDA. Date of first approval: July 2, 2024.

What is the dosage and form of Kisunla® supplied?

Kisunla® is supplied in Injections: 350 mg/20 mL (17.5 mg/mL) in a single-dose vial for intravenous (IV) administration.

What are the most common side effects of Kisunla®? 

The most common side effects of Kisunla® are headache, ARIA with hemosiderin deposition (ARIA-H) microhemorrhage, ARIA with edema (ARIA-E), and ARIA-H superficial siderosis.

How much does Kisunla® 350 mg/20 mL cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on Kisunla 350 mg/20 mL cost in India, it is recommended that you Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Kisunla® be available in SAARC countries? 

Apart from Gulf countries, Kisunla® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the supply of Kisunla® injections in these countries, ensuring access to this therapeutic drug through legal and reliable channels.

Is it safe to buy Kisunla® 350 mg/20 mL injections online in India?

Yes, one can buy Kisunla 350 mg/20 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Kisunla® injections through legal channels. 

What are the storage conditions of Kisunla® 350 mg/20 mL injections?

Store between 2°C to 8°C (36°F to 46°F), keeping the vial in its outer carton to protect it from light. Avoid freezing or shaking.